Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy. The objective of the study is to assess rig...

• Country None
• organs None
• Specialty None

Fluoxetine in Multiple System Atrophy Patients This is a French national trial, conducted using a double-blind, placebo-controlled, randomised design involving 15 centers and 88 patients of both sexes. The primary objective of the tri...

• Country None
• organs None
• Specialty None

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This treatment...

• Country None
• organs None
• Specialty None

Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) This is a French national trial, conducted using a double-blind, placebo-controlled, randomised design involving 7 centers and 80 patients of both sexes. The primary objective of the tria...

• Country None
• organs None
• Specialty None

Fipamezole in Neurogenic Orthostatic Hypotension The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's diseas...

• Country France, Portugal
• organs None
• Specialty None